Coming Monday in BioWorld Insight

March 2013
BioWorld Today;3/22/2013, Vol. 24 Issue 55, p8
The article presents an overview of topics that will be featured in the March 25, 2013 issue of "BioWorld Insight," including early warning signs to combat emerging diseases, a licensing agreement entered by Galena Biopharma Inc. and an online course about epidemics.


Related Articles

  • Deals roundup.  // Medical Device Daily;5/26/2010, Vol. 14 Issue 101, p5 

    This article reports that Valocor Therapeutics has acquired and licensed certain dermatology therapeutic programs from QLT.

  • Agreements/contracts.  // Medical Device Daily;4/18/2012, Vol. 16 Issue 75, p7 

    The article reports on the exclusive worldwide license granted by Dyax to Eclipse Therapeutics for the development and commercialization of preclinical fully-human antibodies discovered through the phage display technology of Dyax for use in oncology indications.

  • Jilted PharmAthene Prevails.  // BioWorld Today;5/29/2013, Vol. 24 Issue 102, p8 

    The article reports on the decision of the Delaware Supreme Court to upheld a lower court ruling that found SIGA Therapeutics Inc. breached its contractual obligation to negotiate a licensing agreement in good faith with PharmAthene Inc.

  • Agreements/contracts.  // Medical Device Daily;10/15/2010, Vol. 14 Issue 201, p3 

    The article reports on a partnership and license agreement between San Diego, California-based Fate Therapeutics and Becton, Dickson and Co. (BD) for the manufacturing and commercialization of induced pluripotent stem cell (iPSC) instruments and technologies for drug development.

  • Pluristem, United Therapeutics Sign $62M Licensing Deal.  // Bioworld Week;6/27/2011, Vol. 19 Issue 26, p3 

    The article reports on the licensing deal signed by Pluristem Ltd. with United Therapeutics Corp. for its PLacental eXpanded (PLX) cell pipeline in the U.S.

  • SEATTLE GENETICS LICENSES PROACTA'S CELL-KILLING DRUGS.  // Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1 

    Deals with the licensing of cell-killing drugs from Proacta Therapeutics by Seattle Genetics Inc. Plans of Seattle Genetics for the drugs; Signficance of the agreement to Seattle Genetics; Background on Proacta Therapeutics.

  • BARRIER ACQUIRES VANIQA CANADIAN DISTRIBUTION RIGHTS.  // Worldwide Biotech;Aug2005, Vol. 17 Issue 8, p1 

    Reports on the distribution rights acquired by Barrier Therapeutics for VANIQA Cream as of August 2005. Terms of the agreement; Product details; Background information on Barrier Therapeutics.

  • COMPANY SPOTLIGHT - Solvay.  // PharmaWatch: CNS;Jan2009, Vol. 8 Issue 1, p16 

    The article presents a corporate profile of Solvay Pharmaceuticals, a developer of therapies for cardiovascular, gastroenterological and neurological disorders, in the U.S. It signed a product licensing agreement with Depomed, wherein it will have an exclusive rights for Gabapentin GR for the...

  • Deal watch: Nektar in US$1.5 billion licensing deal with AstraZeneca.  // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p836 

    The article reports on the licensing deal of U.S.-based Nektar Therapeutics with AstraZeneca PLC for two compounds to combat opioid-induced constipation. The deal entails Nektar to receive an upfront payment of 125 million dollars and up to a total of 1.4 billion dollars in milestone payments....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics